Spots Global Cancer Trial Database for oligoastrocytoma
Every month we try and update this database with for oligoastrocytoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors | NCT00303849 | Anaplastic Olig... Anaplastic Olig... Mixed Glioma Oligoastrocytom... | Carboplatin Etoposide Etoposide Phosp... Laboratory Biom... Mannitol Melphalan Quality-of-Life... Sodium Thiosulf... | 18 Years - 75 Years | OHSU Knight Cancer Institute | |
| Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved | NCT02530320 | Oligodendroglio... Oligoastrocytom... | Palbociclib | 18 Years - | Grupo Español de Investigación en Neurooncología | |
| Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System | NCT04743310 | Central Nervous... | tozuleristide Canvas imaging ... Surgical resect... | 18 Years - | Cedars-Sinai Medical Center | |
| Treatment Strategy for Low-grade Gliomas | NCT00897377 | Astrocytomas Oligodendroglio... Oligoastrocytom... | Radiation thera... Temozolomide | 18 Years - 60 Years | Sun Yat-sen University | |
| SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma | NCT04923126 | Low-Grade Gliom... Recurrent Low-G... Progressive Low... | Mirdametinib | 2 Years - 24 Years | St. Jude Children's Research Hospital | |
| FET-PET for Diagnosis and Monitoring in Patients With Low Grade Glioma | NCT01089244 | Astrocytoma Oligoastrocytom... Oligodendroglio... | 18 Years - | Ludwig-Maximilians - University of Munich | ||
| (11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas | NCT01281982 | Low Grade Gliom... Glioblastoma Mu... Anaplastic Astr... Anaplastic Olig... Oligoastrocytom... | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | ||
| IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma | NCT00089427 | Glioblastoma Mu... Anaplastic Astr... Oligoastrocytom... | IL13-PE38QQR Surgery for pla... Radiation thera... Temozolomide wi... | 18 Years - | INSYS Therapeutics Inc | |
| A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas | NCT02209428 | Astrocytoma Oligodendroglio... Oligoastrocytom... | Temozolomide | 18 Years - 40 Years | Huashan Hospital | |
| FET-PET for Diagnosis and Monitoring in Patients With Low Grade Glioma | NCT01089244 | Astrocytoma Oligoastrocytom... Oligodendroglio... | 18 Years - | Ludwig-Maximilians - University of Munich | ||
| A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma | NCT00389090 | Glioma Astrocytoma Oligodendroglio... Oligoastrocytom... | Temozolomide an... | 18 Years - | Keryx / AOI Pharmaceuticals, Inc. | |
| NovoTTF-200A Device in Treating Patients With Newly Diagnosed High Risk Oligodendroglioma | NCT03353896 | Anaplastic Olig... Oligoastrocytom... Oligodendroglio... | Wear novoTTF-20... Quality-of-Life... | 19 Years - | University of Southern California | |
| Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System | NCT04743310 | Central Nervous... | tozuleristide Canvas imaging ... Surgical resect... | 18 Years - | Cedars-Sinai Medical Center | |
| Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas | NCT01966809 | Brain Tumor, Re... | Photofrin photo... | 18 Years - | Medical College of Wisconsin | |
| HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas | NCT00874861 | Astrocytoma Oligoastrocytom... Oligodendroglio... | Peptide vaccine... | 18 Years - | University of Pittsburgh | |
| Prolonged Daily Temozolomide for Low-Grade Glioma | NCT00165360 | Glioma Astrocytoma Oligodendroglio... | Temozolomide | 18 Years - | Dana-Farber Cancer Institute | |
| Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors | NCT00303849 | Anaplastic Olig... Anaplastic Olig... Mixed Glioma Oligoastrocytom... | Carboplatin Etoposide Etoposide Phosp... Laboratory Biom... Mannitol Melphalan Quality-of-Life... Sodium Thiosulf... | 18 Years - 75 Years | OHSU Knight Cancer Institute | |
| NovoTTF-200A Device in Treating Patients With Newly Diagnosed High Risk Oligodendroglioma | NCT03353896 | Anaplastic Olig... Oligoastrocytom... Oligodendroglio... | Wear novoTTF-20... Quality-of-Life... | 19 Years - | University of Southern California | |
| Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas | NCT04623931 | Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... Diffuse Astrocy... Glioblastoma Oligoastrocytom... Oligodendroglio... WHO Grade II Gl... WHO Grade III G... | Quality-of-Life... Questionnaire A... Radiation Thera... Temozolomide | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma | NCT00389090 | Glioma Astrocytoma Oligodendroglio... Oligoastrocytom... | Temozolomide an... | 18 Years - | Keryx / AOI Pharmaceuticals, Inc. | |
| Trial of IDH305 in IDH1 Mutant Grade II or III Glioma | NCT02977689 | Glioma | IDH305 | 18 Years - | NYU Langone Health | |
| Trial of IDH305 in IDH1 Mutant Grade II or III Glioma | NCT02977689 | Glioma | IDH305 | 18 Years - | NYU Langone Health |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
